Oral lipid-based drug delivery - A case of implementation failing to keep up with innovation?

American Pharmaceutical Review

Volumn 9, Issue 5, 2006, Pages

  Hauss, David J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID;

DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; HYDROPHOBICITY; MEDICAL SOCIETY; REVIEW; SCIENTIST;

EID: 55749106614     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. "Lipid-based Systems for Oral Drug Delivery: Physiological, Mechanistic and Product Development Perspectives". 1997 AAPS Annual Meeting, Boston, MA, November 3, 1997.
2. "Formulating with Lipids" Short Course (AAPS Eastern Regional Meeting, June 3, 1998).
3. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 2004; 58(3):173-182.
4. Gupta SK, Manfro RC, Tomlanovich SJ, Gambertoglio JG, Garovoy MR, Benet LZ. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol 1990; 30:643-53.
5. Vonderscher J, Meinzer A. Rationale for the development of Sandimmune Neoral. Transplant. Proc. 1994; 26:2925-7.
6. Charman WN, Rogge MC, Boddy AW, Berger BM. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J. Clin. Pharmacol. 1993; 33:381-6.
7. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 2004; 47(16):4022-31.
8. Mueller EA, Kovarik JM, van Bree JB, Grevel J, Lucker PW, Kutz K. 1994: Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm. Res. 11:151-155.
9. Cornaire G, Woodley J, Hermann P, Cloare A, Arellano C, Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int. J. Pharm. 2004; 278:119-131.
10. Wandel C, Kim RB, Stein M. "Inactive" excipients such as Cremophor can affect in vivo drug disposition. Clin. Pharm. Ther. 2003; 73(5):394- 396.
11. Charman WN. Lipid vehicle and formulation effects on intestinal lymphatic drug transport. In: Charman WN, Stella VJ, eds. Lymphatic Transport of Drugs. Boca Raton: CRC Press, 1992:113-179.
12. Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, Keirns JJ. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J. Pharm. Sci. 1998; 87:164-9.
13. Rege B, Kao J, Polli J. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. J. Pharm. Sci. 2002; 16:237-46.
14. Zangenberg NH, Mullertz A, Gjelstrup KH, Hovgaard L. A dynamic in vitro lipolysis model. II: Evaluation of the model. Eur J. Pharm. Sci. 2001; 14:237-244.
15. Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. J. Pharm. Sci. 2000 11(Suppl. 2):73-80.
16. Strickley R. Solubilizing excipients in oral and injectable formulations.Pharm Res. 2004; 21(2):201-30.
17. Taylor D. BMJ 2003; 326:407-408.
18. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. U.S. Department of Health and Human Services, Food and Drug Administration. March, 2004. 32 American Pharmaceutical Review